Friday, 30 October 2026European Markets

COHERIS Stock Is 11% Down So Far On Friday

Loading stream...

(vianews) - shares of coheris (cac 40: coh.pa) slid by a staggering 11.25% to €4.26 at 14:52 est on friday, after two successive sessions in a row of gains. cac 40 is falling 0.16% to €7,191.86, after four successive sessions in a row of losses. this seems, as yet, a somewhat bearish trend trading session today.

coheris's last close was €4.80, 7.69% below its 52-week high of €5.20.

about coheris

coheris sa provides customer relationship management (crm) and analytics solutions in france and internationally. the company offers data solutions, such as digital and speech intelligence, cyber security, data science, data operating system, data mining and machine learning, and business intelligence and analytics. it also provides crm customer service, sales force, and marketing; and unified commerce, including digital in-store, order management system, e-merchandising and searchandsing, wen-to-store, store management, unified stocks, returns and refunds, and clienteling, as well as product recommendation, seller performance optimization, look book, and digital asset management services. in addition, the company offers merchandising, and e-merchandising and search software; marketing automation; and last mile logistics services. it serves bank and finance, mutual insurance, consumer goods and gics, retail, agrifood, otc and pharmacy, out-of-home consumption, industry, luxury premium, audience, and regalian sectors. the company is based in suresnes, france. coheris sa is as subsidiary of chapsvision.

earnings per share

as for profitability, coheris has a trailing twelve months eps of €0.79.

pe ratio

coheris has a trailing twelve months price to earnings ratio of 5.39. meaning, the purchaser of the share is investing €5.39 for every euro of annual earnings.

more news about coheris (coh.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com